Selected article for: "ebov infection and GP rvsv infection"

Author: Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy
Title: Interferon-? Inhibits Ebola Virus Infection
  • Document date: 2015_11_12
  • ID: 10bu7iwg_10
    Snippet: The ability of IFNγ, but not TNFα, to inhibit virus infection was also demonstrated in human macrophages. In these studies, six-day M-CSF matured human monocyte derived macrophages (hMDMs) were treated for 24 hours prior to infection with TNFα and/or IFNγ. Similar to our murine macrophages findings, M-CSF-matured hMDMs were highly permissive for EBOV GP/rVSV infection and human IFNγ, but not TNFα, effectively and profoundly blocked the numb.....
    Document: The ability of IFNγ, but not TNFα, to inhibit virus infection was also demonstrated in human macrophages. In these studies, six-day M-CSF matured human monocyte derived macrophages (hMDMs) were treated for 24 hours prior to infection with TNFα and/or IFNγ. Similar to our murine macrophages findings, M-CSF-matured hMDMs were highly permissive for EBOV GP/rVSV infection and human IFNγ, but not TNFα, effectively and profoundly blocked the number of cells infected by our recombinant virus (Fig 1C) . In a dose-dependent manner, 200 pg/mL reduced EBOV GP/rVSV replication by about 10-fold and 20 ng/mL reduced titers as assessed by end point dilution by more than four orders of magnitude ( Fig 1D) . In addition, we determined if human IFNγ inhibits EBOV GP/rVSV infection of an in vivo matured macrophage population, human alveolar macrophages. These cells were isolated by bronchial lavage and phenotyped as previously described [26, 27] . Similar to the MDM cultures, M-CSF-treated cells were permissive for virus, whereas the addition of IFNγ prevented infection of these cells (Fig 1E) .

    Search related documents:
    Co phrase search for related documents
    • dose dependent manner and EBOV GP rvsv: 1, 2
    • dose dependent manner and EBOV GP rvsv infection: 1, 2
    • dose dependent manner and EBOV GP rvsv replication: 1
    • dose dependent manner and GP rvsv: 1, 2
    • dose dependent manner and GP rvsv infection: 1, 2
    • dose dependent manner and human monocyte: 1, 2
    • EBOV GP rvsv and end point dilution: 1, 2, 3
    • EBOV GP rvsv and GP rvsv: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • EBOV GP rvsv and GP rvsv infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • EBOV GP rvsv and human IFNγ: 1
    • EBOV GP rvsv and human macrophage: 1
    • EBOV GP rvsv infection and GP rvsv: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • EBOV GP rvsv infection and GP rvsv infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • EBOV GP rvsv infection and human IFNγ: 1
    • EBOV GP rvsv replication and GP rvsv: 1, 2, 3
    • EBOV GP rvsv replication and GP rvsv infection: 1, 2, 3
    • end point dilution and GP rvsv: 1, 2, 3
    • end point dilution and human macrophage: 1
    • GP rvsv and human macrophage: 1